PB2326: SAFE AND EFFECTIVE PROPHYLAXIS WITH PLASMA-DERIVED FACTOR X CONCENTRATE IN AN ELDERLY PATIENT WITH HEREDITARY FACTOR X DEFICIENCY

por Patel, H., Peltier, S., Clark, K., Reding, M. T.
Publicado 2022

Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A

por Coyle, T E, Reding, M T, Lin, J C, Michaels, L A, Shah, A, Powell, J
Publicado 2014

Design of the HEM-POWR study: a prospective, observational study of real-world treatment with damoctocog alfa pegol in patients with haemophilia A

por Sanabria, Martin, Álvarez Román, María Teresa, Castaman, Giancarlo, Janbain, Maissaa, Matsushita, Tadashi, Meijer, Karina, Oldenburg, Johannes, Friedl, Sabine, Reding, M T
Publicado 2021